Oregon Public Employees Retirement Fund Has $954,000 Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Oregon Public Employees Retirement Fund raised its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,600 shares of the biotechnology company’s stock after acquiring an additional 700 shares during the period. Oregon Public Employees Retirement Fund’s holdings in ADMA Biologics were worth $954,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ADMA. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock worth $13,171,000 after buying an additional 80,400 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of ADMA Biologics during the 3rd quarter worth $61,858,000. EWG Elevate Inc. acquired a new position in shares of ADMA Biologics during the 4th quarter worth $480,000. Citigroup Inc. raised its holdings in shares of ADMA Biologics by 251.7% during the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock worth $7,741,000 after buying an additional 277,138 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock worth $51,016,000 after acquiring an additional 2,613,482 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADMA has been the topic of a number of research reports. HC Wainwright boosted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James boosted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Trading Up 6.2 %

NASDAQ ADMA opened at $16.39 on Friday. The business’s 50-day moving average price is $16.73 and its two-hundred day moving average price is $17.98. ADMA Biologics, Inc. has a 12 month low of $5.08 and a 12 month high of $23.64. The firm has a market capitalization of $3.87 billion, a PE ratio of 58.54 and a beta of 0.75. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.